《大行报告》汇丰研究上调君实生物(01877.HK)目标价至95元 评级「买入」
汇丰研究发表报告,上调今、明两年收入预期86%及19%,以反映新冠双抗体疗法Etesevimab(JS016)获美国FDA紧急使用授权,以及抗PD-1单抗产品特瑞普利单抗注射液「拓益」海外授权等利好因素。
该行认为,君实生物研发及商业化稳步发展,正逐步发展成一家生物技术平台公司,认为过去两个月股价虽表现强劲,但估值仍然具有吸引力。
汇丰研究解释,拓益及JS016的海外合作将为今年收入增长作支持,加上公司有不少项目已递交各阶段的新药上市申请,料成为股价催化剂。该行指出,君实2022年预测市销率为15.8倍,较同业平均水平约17.3倍低,维持「买入」评级,目标价由66元上调至95元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.